| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | DNALI1 |
| Uniprot No | O14645 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-280aa |
| 氨基酸序列 | MGSSHHHHHH SSGLVPRGSH MGSMVTANKA HTGQGSCWVA TLASAMIPPA DSLLKYDTPV LVSRNTEKRS PKARLLKVSP QQPGPSGSAP QPPKTKLPST PCVPDPTKQA EEILNAILPP REWVEDTQLW IQQVSSTPST RMDVVHLQEQ LDLKLQQRQA RETGICPVRR ELYSQCFDEL IREVTINCAE RGLLLLRVRD EIRMTIAAYQ TLYESSVAFG MRKALQAEQG KSDMERKIAE LETEKRDLER QVNEQKAKCE ATEKRESERR QVEEKKHNEE IQFLKRTNQQ LKAQLEGIIA PKK |
| 预测分子量 | 34 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于DNALI1重组蛋白的3篇参考文献及其摘要内容概述：
1. **文献名称**：*"Recombinant DNALI1 facilitates structural analysis of dynein light intermediate chains in ciliary motility"*
**作者**：Smith J, et al.
**摘要**：研究通过重组表达DNALI1蛋白，结合冷冻电镜技术解析其与动力蛋白复合体的相互作用，揭示了其在纤毛运动调控中的关键结构域及突变导致的动力障碍机制。
2. **文献名称**：*"Functional characterization of DNALI1 mutations in primary ciliary dyskinesia using recombinant protein models"*
**作者**：Chen L, et al.
**摘要**：利用重组DNALI1蛋白模拟人类原发性纤毛运动障碍(PCD)相关突变，发现特定突变位点破坏其与动力蛋白重链的结合能力，导致纤毛摆动功能异常。
3. **文献名称**：*"Expression and purification of human DNALI1 in E. coli for antibody production"*
**作者**：Kumar R, et al.
**摘要**：报道了一种高效的原核表达系统制备重组人DNALI1蛋白的方法，纯化后蛋白成功用于制备特异性抗体，为疾病诊断及分子机制研究提供了工具。
注：以上文献信息为模拟示例，实际文献需通过PubMed或Google Scholar检索确认。若需真实文献，建议使用关键词“DNALI1 recombinant protein”或结合疾病关键词(如“primary ciliary dyskinesia”)进一步筛选。
**Background of DNALI1 Recombinant Protein**
DNALI1 (Dynein Axonemal Light Intermediate Chain 1) is a protein encoded by the *DNALI1* gene, belonging to the dynein light intermediate chain family. It plays a critical role in the structure and function of cytoplasmic and axonemal dyneins, motor proteins essential for intracellular transport and the movement of cilia and flagella. DNALI1 is particularly associated with the assembly and stability of dynein complexes in cilia, contributing to their motility and signaling functions. Mutations in *DNALI1* have been linked to primary ciliary dyskinesia (PCD), a genetic disorder characterized by impaired mucociliary clearance, chronic respiratory infections, and infertility due to dysfunctional cilia and flagella.
Recombinant DNALI1 protein is produced using heterologous expression systems (e.g., *E. coli* or mammalian cells*) to study its biochemical properties, interactions, and role in ciliary biology. It serves as a vital tool for investigating dynein complex formation, ciliary motility mechanisms, and disease pathogenesis. Researchers utilize this protein in assays such as pull-down experiments, structural analyses, and functional studies to identify binding partners or assess the impact of pathogenic mutations. Its applications extend to drug screening and therapeutic development targeting cilia-related disorders.
The availability of recombinant DNALI1 facilitates advances in understanding ciliary dynamics and molecular defects underlying PCD, offering potential pathways for diagnostics and treatments.
×
